Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIstradefylline
Description: Potent and selective A2A antagonist
Alternative Names: KW-6002
Chemical Name: 8-[(1E)-2-(2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione
Purity: ≥99% (HPLC)
Biological Activity for Istradefylline
Istradefylline is a potent and selective adenosine A2A receptor antagonist (Ki values are 2.2 and 150 nM for A2A and A1 receptors respectively). Anticataleptic and antiparkinson agent; reverses drug-induced motor dysfunction in animal models.
Technical Data for Istradefylline
| M. Wt | 384.43 |
| Formula | C20H24N4O4 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 155270-99-8 |
| PubChem ID | 5311037 |
| InChI Key | IQVRBWUUXZMOPW-PKNBQFBNSA-N |
| Smiles | O=C1N(CC)C(C(N(C)C(/C=C/C3=CC(OC)=C(OC)C=C3)=N2)=C2N1CC)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Istradefylline
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 7.69 | 20 |
Preparing Stock Solutions for Istradefylline
The following data is based on the product molecular weight 384.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.2 mM | 13.01 mL | 65.03 mL | 130.06 mL |
| 1 mM | 2.6 mL | 13.01 mL | 26.01 mL |
| 2 mM | 1.3 mL | 6.5 mL | 13.01 mL |
| 10 mM | 0.26 mL | 1.3 mL | 2.6 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Istradefylline
References for Istradefylline
References are publications that support the biological activity of the product.
Shimada et al (1997) Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg.Med.Chem.Lett. 7 2349
Kanda et al (1998) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9 2857 PMID: 9760134
Shiozaki et al (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by rese. or MPTP. Psychopharmacology 147 90 PMID: 10591873
If you know of a relevant reference for Istradefylline, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Istradefylline, Istradefylline supplier, Potent, selective, Adenosine, A2A, receptor, antagonists, KW-6002, KW6002, AA2AR, antiparkinsons, activity, antiparkinsonian, anticataleptics, Receptors, 5147, Tocris Bioscience
3 Citations for Istradefylline
Citations are publications that use Tocris products. Selected citations for Istradefylline include:
Wydra et al (2015) On the role of A2A and D2 receptors in control of cocaine and food-seeking behaviors in rats. PLoS One 232 1767 PMID: 25420611
Orr et al (2018) Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis 110 29 PMID: 29100987
Cheng et al (2017) Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. Structure 25 1275 PMID: 28712806
Do you know of a great paper that uses Istradefylline from Tocris? Please let us know.
Reviews for Istradefylline
Average Rating: 4 (Based on 1 Review.)
Have you used Istradefylline?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Istradefylline on D2R antagonist induced motor impairment.
By
Yunmin Ding on 12/07/2018
Assay Type: In Vivo
Species: Mouse
i.p.
Istradefylline from Tocris worked wonderfully. At 3 mg/kg (in suspension in 8% Tween 80 in 0.9% saline), it reversed motor impairment induced by 0.16 mg/kg of the D2R antagonist eticlopride
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Parkinson's PosterUpdated
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.